<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41784">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562417</url>
  </required_header>
  <id_info>
    <org_study_id>CER 478/14</org_study_id>
    <nct_id>NCT02562417</nct_id>
  </id_info>
  <brief_title>Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex</brief_title>
  <official_title>Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sugammadex is used as a reversal drug for rocuronium- or vecuronium-induced neuromuscular
      block during general anaesthesia. IV dexamethasone is injected as a prophylactic measure
      against postoperative nausea and vomiting. Recent animal data have shown that dexamethasone
      may impair the reversal effect of sugammadex. The objective of this randomised controlled
      trial is to confirm in the clinical practice these preliminary results.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean recovery time for T4/T1 ratio &gt; 90% after sugammadex administration</measure>
    <time_frame>surgical procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean recovery time for T4/T1 ratio &gt; 80% after sugammadex administration</measure>
    <time_frame>surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean recovery time for T4/T1 ratio &gt; 70% after sugammadex administration</measure>
    <time_frame>surgical procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>No IV dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive an equivalent volume of normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.1 mg/kg of dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>No IV dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV dexamethasone</intervention_name>
    <arm_group_label>IV dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled to undergo microlaryngoscopy and ear-nose-throat endoscopic
             procedures

        Exclusion Criteria:

          -  contraindication to dexamethasone administration

          -  contraindication to sugammadex administration

          -  contraindication to rocuronium administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Albrecht, MD</last_name>
    <phone>+41 79 556 63 41</phone>
    <email>eric.albrecht@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecile Courbon, MD</last_name>
    <phone>+41 21 314 20 07</phone>
    <email>cecile.courbon@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <state>VAud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecile Courbon</last_name>
      <phone>+41213141111</phone>
      <email>cecile.courbon@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 23, 2016</lastchanged_date>
  <firstreceived_date>September 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Albrecht</investigator_full_name>
    <investigator_title>Program Director, Regional Anaesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
